-

11:27:16 PM

LNTH Stock News

LNTH - Lantheus Holdings Inc

02/10/22 8:30 AM

Nasdaq : LNTH

conferencesearnings

Lantheus Holdings to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on February 24, 2022 at 8:00 a.m. Eastern Time

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 24, 2022, to discuss its financial and operating results for the fourth quarter

RHEA-AI

neutral

01/27/22 8:30 AM

Nasdaq : LNTH

clinical trial

Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB (EXINI), has entered into a collaboration with the Prostate Cancer Clinical Trials Consortium (PCCTC) to advance artificial intelligence

RHEA-AI

very positive

12/01/21 8:30 AM

Nasdaq : LNTH

management

Lantheus Appoints Vivian Yao as Chief Human Resources Officer

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow

RHEA-AI

positive

11/29/21 8:30 AM

Nasdaq : LNTH

Lantheus Announces PYLARIFY AI™ is Now Available

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider

RHEA-AI

neutral

11/22/21 8:30 AM

Nasdaq : LNTH

Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed

RHEA-AI

very positive

11/17/21 8:30 AM

Nasdaq : LNTH

Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targeted Prostate Cancer Imaging Agent, at Key Scientific Meetings

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow

RHEA-AI

neutral

11/16/21 4:30 PM

Nasdaq : LNTH

conferences

Lantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx Conference

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow

RHEA-AI

neutral

11/04/21 7:00 AM

Nasdaq : LNTH

earnings

Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results

Worldwide revenue of $102.1 million for the third quarter 2021, representing an increase of 15.3% from the prior year period GAAP net loss of $13.4 million for the third quarter 2021, compared to GAAP net loss of $6.4 million in the prior year period GAAP fully diluted net loss of $0.20 for the

RHEA-AI

neutral

10/28/21 4:30 PM

Nasdaq : LNTH

conferences

Lantheus Holdings to Present at Upcoming Investor Conferences

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow

RHEA-AI

neutral

10/21/21 8:00 AM

Nasdaq : LNTH

conferencesearnings

Lantheus Holdings to Host Third Quarter 2021 Earnings Conference Call and Webcast on November 4, 2021 at 8:00 a.m. Eastern Time

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 4, 2021, to discuss its financial and operating results for the third quarter of

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 Next

LNTH Data

Websiteinvestor.lantheus.com
CeoMary Heino
Security nameLantheus Holdings Inc
Issue typecs
Sic code2835
Employees595
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Surgical and Medical Instrument Manufacturing
Address331 Treble Cove Rd
StateMassachusetts
CityNorth Billerica
Zip01862-2849
CountryUS
Phone19786718001

About Lantheus Holdings Inc

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow™ serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden.